Komori
Kohjin Bio (177A) · TargetAdvanced

Entry into Contract Manufacturing of Cells for Clinical Trials of Regenerative Medical Products

First written in FY2024. 2 of 4 entries say "Advanced", first in FY2025-H1. Latest entry: FY2026.

4entries
3years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2024AdvancedFY2025-H1 – FY20262024: 220242025: 120252026: 12026
Same theme, other companies
Launch of a Regenerative Medicine CDMO and Contract Cell Manufacturing BusinessA theme 13 companies write about · 1 as a headwind · 20 as a tailwind

The whole theme swung hardest in 2025: 1 of 11 companies on the "Worse" side.

6 other companies' latest entry also says "Advanced".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
  1. FY2026AdvancedAnnual report

    「Head office (Sakado, Saitama Prefecture) / Cell processing business / Cell processing facility / 388,084 / 320,984 / Internal funds / June 2025 / November 2026 / Approximately 1,000 specimens」

    Following completion of its entry into the CDMO business, the company is developing a new cell processing facility on the fifth floor of its warehouse, with planned capacity for approximately 1,000 specimens.
  2. FY2025AchievedAnnual report

    「To serve as a facility for these activities, the company has established a new cell processing facility and entered the contract manufacturing business for cells used in clinical trials of regenerative medicine products, namely the CDMO business.」

    The company states that it has completed the establishment of the planned cell processing facility and entered the contract manufacturing business for cells used in clinical trials.
  3. FY2025-H1AdvancedAnnual report

    「The company is preparing to commence operations at the newly established cell processing facility in Hiroshima Prefecture and expects the facility to become fully operational during the current fiscal year.」

    The planned cell processing facility has been newly established in Hiroshima Prefecture, and preparations are under way for full-scale operations.
  4. FY2024First statedAnnual report

    「The company will establish a new cell processing facility and enter the contract manufacturing business for cells used in clinical trials of regenerative medicine products, namely the CDMO business.」

    The company plans to establish a new facility and begin contract manufacturing of cells for clinical trials.
Moved together

"Expansion of Production Facilities and Strengthening of R&D Capabilities" moved the same way as this thread, in the same document, in 3 of its 4 moves.

333222★123456
  1. ★This thread
  2. 1Expansion of Production Facilities and Strengthening of R&D Capabilities3×
  3. 2Expansion of the Regenerative Medicine Market3×
  4. 3Listing on the Tokyo Stock Exchange Growth Market and growth investment3×
  5. 4Expansion of Culture Media Product Lineup, Production Technology and Sales Organization2×
  6. 5Development and commercial launch of media for CHO and HEK293 cells2×
  7. 6Development and launch of rapid infectious disease test kits for Asia2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for Kohjin Bio yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Entry into Contract Manufacturing of Cells for Clinical Trials of Regenerative Medical Products | Kohjin Bio Co.,Ltd. (177A) | Komori